1-Methyl-4-phenylpyridinium (MPP+) does not exhibit paraquat-like immunoreactivity.
The structural analogy of paraquat with 1-methyl-4-phenylpyridinium (MPP+) has been implied in the aetiology of Parkinson's disease. The cross-reactivity of MPP+ to a specific antibody to paraquat was assessed by radioimmunoassay and was found to be very low. The results suggest that this polyclonal paraquat antibody does not mimic the MPP+ receptor.
Houzé
P
P
INSERM U26, Hôpital Fernand Widal, Paris, France.
Chappey
O
O
Gallons
H
H
Scherrmann
J M
JM
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000276:immunology; D015655:1-Methyl-4-phenylpyridinium / Q000737:chemistry / Q000276:immunology*; D000906:Antibodies / Q000276:immunology; D003429:Cross Reactions; D006801:Humans; D008968:Molecular Conformation; D010269:Paraquat / Q000737:chemistry / Q000276:immunology*; D011863:Radioimmunoassay
D000906:Antibodies; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D010269:Paraquat; D015655:1-Methyl-4-phenylpyridinium